Hypofractionated/accelerated radiotherapy with cytoprotection (HypoARC) combined with vinorelbine and liposomal doxorubicin for locally advanced non-small cell lung cancer (NSCLC)

Anticancer Research

Volumn 28, Issue 2 B, 2008, Pages 1349-1354

  Tsoutsou, Pelagia G ^a   Froudarakis, Marios E ^a   Bouros, Demosthenes ^a   Koukourakis, Michael I ^a,b  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

Author keywords

Acceleration; Amifostine; Hypofractionation; Liposomal doxorubicin; Non small cell lung cancer; Radiotherapy; Vinorelbine

Indexed keywords

AMIFOSTINE; DOXORUBICIN; NAVELBINE;

ADULT; AGED; ANEMIA; ARTICLE; BRAIN DISEASE; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER SURVIVAL; CELL PROTECTION; CLINICAL ARTICLE; ESOPHAGITIS; FATIGUE; FEMALE; FEVER; HUMAN; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUROSENSORY DEFICIT; NEUTROPENIA; PLEURA EFFUSION; PRIORITY JOURNAL; RADIATION PNEUMONIA; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

AGED; AMIFOSTINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, NON-SMALL-CELL LUNG; COMBINED MODALITY THERAPY; DOSE FRACTIONATION; DOXORUBICIN; FEASIBILITY STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; RADIATION-PROTECTIVE AGENTS; VINBLASTINE;

EID: 42549087671     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. NCCN Clinical Practice Guidelines in Oncology, Non-small Cell Lung Cancer, Version 2.2006 MS-10.
2. Pfister DG, Johnson DH, Azzoli CG, Sause W, Smith TJ, Baker S Jr, Olak J, Stover D, Strawn JR, Turrisi AT and Somerfield MR: American Society of Clinical Oncology. American Society of Clinical Oncology Treatment of Unresectable Non-small Cell Lung Cancer Guideline: Update 2003. J Clin Oncol 22: 330-353, 2004.
3. Fournel P, Robinet G, Thomas P, Souquet PJ, Lena H, Vergnenegre A, Delhoume JY, Le Treut J, Silvani JA, Dansin E, Bozonnat MC, Daures JP, Mornex F and Perol M: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiofherapy in locally advanced non-small cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francais de Pneumo-Cancerologie NPC 95-01 Study. J Clin Oncol 23: 5910-5917, 2005.
4. Shepherd FA: Current paradigms in first-line treatment of non-small-cell lung cancer. Oncology 18(8 Suppl 5): 13-20, 2004.
5. Jassem J, Kosmidis P, Ramlau R, Zarogoulidis K, Novakova L, Breton J, Etienne PL, Seebacher C, Grivaux M, Ojala A, Aubert D and Lefresne F: Oral vinorelbine in combination with cisplatin: a novel active regimen in advanced non-small-cell lung cancer. Ann Oncol 14: 1634-1639, 2003.
6. Numico G, Castiglione F, Granetto C, Garrone O, Mariani G, Costanzo GD, Ciura PL, Gasco M, Ostellino O, Porcile G and Merlano M: Single-agent pegylated liposomal doxorubicin (Caelix) in chemotherapy pretreated non-small cell lung cancer patients: a pilot trial. Lung Cancer 35: 59-64, 2002.
7. Patlakas G, Bouros D, Tsantekidou-Pozova S and Koukourakis MI: Triplet chemotherapy with docetaxel, gemcitabine and liposomal doxorubicin, supported with subcutaneous amifostine and hemopoietic growth factors, in advanced non-small cell lung cancer. Anticancer Res 25: 1427-1432, 2005.
8. Koukourakis MI, Koukouraki S, Giatromanolaki A, Archimandritis SC, Skarlatos J, Beroukas K, Bizakis JG, Retalis G, Karkavitsas N and Helidonis ES: Liposomal doxorubicin and conventionally fractionated radiotherapy in the treatment of locally advanced non-small cell lung cancer and head and neck cancer. J Clin Oncol 17: 3512-3521, 1999.
9. Koukourakis MI, Romanidis K, Froudarakis M, Kyrgias G, Koukourakis GV, Retalis G and Bahlitzanakis N: Concurrent administration of docetaxel and stealth liposomal doxorubicin with radiotherapy in non-small cell lung cancer: excellent tolerance using subcutaneous amifostine for cytoprotection. Br J Cancer 87: 385-392, 2002.
10. Varveris H, Kachris S, Mazonakis M, Lyraraki E, Markouizou A, Karabekios S, Tzedakis A, Perisinakis K, Damilakis J and Vlachaki M: Pegulated liposomal doxorubicin and cisplatin given concurrently with conventional radiotherapy: a phase I dose-escalation trial for patients with squamous cell carcinoma of head and neck and lung. Oncol Rep 12: 473-481, 2004.
11. Koukourakis MI: Hypofractionated and accelerated radiotherapy with amifostine cytoprotection (HypoARC): a new concept in radiotherapy and encouraging results in breast cancer. Semin Oncol 29: 42-46, 2002.
12. Koukourakis MI, Abatzoglou I, Sivridis L, Tsarkatsi M and Delidou H: Individualization of the subcutaneous amifostine dose during hypofractionated/accelerated radiotherapy. Anticancer Res 26: 2437-2444, 2006.
13. Koukourakis M, Hlouverakis G, Kosma L, Skarlatos J, Damilakis J, Giatromanolaki A and Yannakakis D: The impact of overall treatment time on the results of radiotherapy for non small cell lung carcinoma. Int J Radiat Oncol Biol Phys 34: 315-322, 1996.
14. Cancer Therapy Evaluation Program, Common Terminology Criteria for Adverse Events, Version 3.0, DCTD, NCI, NIH, DHHS, March 31, 2003, (http://ctep.cancer.gov). Publish Date, August 9, 2006
15. Fukuoka K, Arioka H, Iwamoto Y, Fukumoto H, Kurokawa H, Ishida T, Tomonari A, Suzuki T, Usuda J, Kanzawa F, Saijo N and Nishio K: Mechanism of the radiosensitization induced by vinorelbine in human non-small cell lung cancer cells. Lung Cancer 34: 451-460, 2001.
16. Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C, Guttman T, Todor N and Ghilezan N: Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study. J BUON 12: 33-39, 2007.
17. Sekine I, Nokihara H, Sumi M, Saijo N, Nishiwaki Y, Ishikura S, Mori K, Tsukiyama I and Tamura T: Docetaxel consolidation therapy following cisplatin, vinorelbine, and concurrent thoracic radiotherapy in patients with unresectable stage III non-small cell lung cancer. J Thorac Oncol 1: 810-815, 2006.
18. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P, Klautke G and Fietkau R: 6-Year experience of concurrent radiochemotherapy with vinorelbine plus a platinum compound in multimorbid or aged patients with inoperable non-small cell lung cancer. Strahlenther Onkol 183: 30-35, 2007 (English).
19. Kobayashi M, Matsui K, Hirashima T, Nitta T, Sasada S, Tada T, Minakuchi K,Furukawa M, Ogata Y and Kawase I: Phase I study of weekly cisplatin, vinorelbine, and concurrent thoracic radiation therapy in patients with locally advanced non-small cell lung cancer. Int J Clin Oncol 11: 314-319, 2006.
20. Hirose T, Mizutani Y, Ohmori T, Ishida H, Hosaka T, Ando K, Shirai T, Okuda K, Ohnishi T, Horichi N, Kubota H and Adachi M: The combination of cisplatin and vinorelbine with concurrent thoracic radiation therapy for locally advanced stage IHA or HIB non-small cell lung cancer. Cancer Chemother Pharmacol 58: 361-367, 2006.
21. Michael M, Wirth A, Ball DL, MacManus M, Rischin D, Mileshkin L, Solomon B, McKendrick J and Milner AD: A phase I trial of high-dose palliative radiotherapy plus concurrent weekly Vinorelbine and Cisplatin in patients with locally advanced and metastatic NSCLC. Br J Cancer 93: 652-661, 2005.
22. Winterhaider R, Deschler-Marini S, Landmann C, Kann R, Passweg J, Herrmann R and Pless M: Vinorelbine plus low-dose cisplatinum with concomitant radiotherapy for the treatment of locally advanced or inoperable non-metastasized non-small cell lung cancer (stage I-IIIB): a phase II study. Radiother Oncol 73: 321-324, 2004.
23. Zatloukal P, Petruzelka L, Zemanova M, Havel L, Janku F, Judas L, Kubik A, Krepela E, Fiala P and Pecen L: Concurrent versus sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 46: 87-98, 2004.
24. Sekine I, Noda K, Oshita F, Yamada K, Tanaka M, Yamashita K, Nokihara H, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, Sumi M and Saijo N: Phase I study of cisplatin, vinorelbine, and concurrent thoracic radiotherapy for unresectable stage III non-small cell lung cancer. Cancer Sci 95: 691-695, 2004.
25. Argiris A, Liptay M, LaCombe M, Marymont M, Kies MS, Sundaresan S and Masters G: A phase I/II trial of induction chemotherapy with carboplatin and gemcitabine followed by concurrent vinorelbine and paclitaxel with chest radiation in patients with stage III non-small cell lung cancer. Lung Cancer 45: 243-253, 2004.
26. Reguart N, Vinolas N, Casas F, Gimferrer JM, Agusti C, Molina R, Martin-Richard M, Sanchez-Reyes A and Gascon P: Integrating concurrent navelbine and cisplatin to hyperfractionated radiotherapy in locally advanced non-small cell lung cancer patients treated with induction and consolidation chemotherapy: feasibility and activity results. Lung Cancer 45: 67-75, 2004.
27. Semrau S, Bier A, Thierbach U, Virchow C, Ketterer P and Fietkau R: Concurrent radiochemotherapy with vinorelbine plus cisplatin or carboplatin in patients with locally advanced non-small cell lung cancer (NSCLC) and an increased risk of treatment complications. Preliminary results. Strahlenther Onkol 179: 823-831, 2003 (English).
28. Vokes EE, Herndon JE 2nd, Crawford J, Leopold KA, Perry MC, Miller AA, Green MR, Vokes EE, Herndon JE and Crawford J: Randomized phase II study of cisplatin with gemcitabine or paclitaxel or vinorelbine as induction chemotherapy followed by concomitant chemoradiotherapy for stage HIB non-small cell lung cancer: cancer and leukemia group B study 9431. J Clin Oncol 20: 4191-4198, 2002.
29. Hoffman PC, Cohen EE, Masters GA, Haraf DJ, Mauer AM, Rudin CM, Krauss SA, Huo D and Vokes EE: Carboplatin plus vinorelbine with concomitant radiation therapy in advanced non-small cell lung cancer: a phase I study. Lung Cancer 38: 65-71, 2002.
30. Cassatt DR, Fazenbaker CA, Kifle G and Bachy CM: Effects of dose and schedule on the efficacy of ethyol: preclinical studies. Semin Oncol 30(Suppl): S31-39, 2003.